Latest Manufacturing Partnerships News

Pure One Corporation Limited has advanced its zero-emission mobility strategy with a new local vehicle assembly partnership, expanded US hydrogen market collaborations, and progressed the spin-out of its Australian gas assets via Eastern Gas IPO.

Tissue Repair’s December quarter update reveals a cautious path forward for its Phase 3 TR987 trial amid slow patient recruitment, while its TR Pro+ product line gains momentum through a new distributor partnership and upcoming product launches.

Zimi Limited has reported a striking 300% year-on-year revenue surge alongside the industrialisation of its next-generation Senoa Matter smart home range, signalling a pivotal moment in its growth and market positioning.

Peak Processing has significantly expanded its manufacturing partnership with St. Peter’s Beverages, tripling its SKU production and boosting annual output by up to 700,000 units. This move strengthens its foothold in North America’s cannabis beverage market using proprietary technology.

Pure Foods Tasmania has launched contract manufacturing with Brilliant Food Australia, marking a significant step in utilising its Woodbridge Smokehouse facility and expanding regional employment.

Uscom Limited reported a 25% revenue decline in FY25 amid global geopolitical challenges but reinforced its commitment to growth through strategic partnerships and innovative medical technologies.

Clarity Pharmaceuticals has raised $203 million to accelerate its copper-64 and copper-67 radiopharmaceutical pipeline, targeting prostate and neuroendocrine cancers with multiple FDA Fast Track trials underway.

Autosports Group is set to acquire ten Barry Bourke Motors dealerships in Victoria for $34 million, expanding its luxury automotive footprint and strengthening key manufacturer partnerships.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

Chimeric Therapeutics has progressed its CHM CDH17 and CHM CORE-NK clinical trials with promising safety and efficacy signals, while securing a key manufacturing partnership and appointing a renowned haematologist to its board. However, the company faces a pressing cash runway challenge.

NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.

Dyno Nobel has finalised the sale of its Fertilisers Distribution business and is advancing strategic shifts including a new US TNT manufacturing partnership, underpinning a strong FY25 outlook.